GlassScriptPhysician profile
Felipe Albuquerque
NPI 1851605661
$20,785.83
in general payments reported to CMS, 2019-2025
16 companies · $4,141 in 2025
The $4,141 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,357 · 2020: $1,476 · 2021: $2,620 · 2022: $2,221 · 2023: $2,158 · 2024: $6,811 · 2025: $4,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,550 · Food and Beverage: $2,878 · Travel and Lodging: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,550.00 |
| Food and Beverage | $2,878.17 |
| Travel and Lodging | $1,682.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $14,202.09 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $1,877.18 | 2020-2025 | Triclip, Optis, Cardiomems |
| Medtronic, INC. | $1,284.26 | 2021-2025 | Ffrangio, Corevalve Evolut R, Resolute Onyx |
| Medtronic Vascular, INC. | $1,058.71 | 2019-2020 | |
| Philips North America LLC | $786.79 | 2024-2025 | Igt Devices Undivided, (Bq9) Coronary Ivus |
| Biotronik INC. | $406.75 | 2022 | |
| Boston Scientific Corporation | $380.53 | 2019-2024 | Watchman Access System |
| Shockwave Medical, INC | $169.67 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $157.63 | 2021 | |
| Amgen INC. | $142.06 | 2019-2025 | Repatha |
| Alnylam Pharmaceuticals INC. | $90.95 | 2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $73.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.99 | 2019-2024 | Wainua |
| Pfizer INC. | $37.15 | 2022-2023 | |
| Heartflow, INC. | $31.73 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $24.07 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Albuquerque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.